1. Home
  2. ICCM vs IRD Comparison

ICCM vs IRD Comparison

Compare ICCM & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICCM
  • IRD
  • Stock Information
  • Founded
  • ICCM 2006
  • IRD 2018
  • Country
  • ICCM Israel
  • IRD United States
  • Employees
  • ICCM N/A
  • IRD N/A
  • Industry
  • ICCM
  • IRD
  • Sector
  • ICCM
  • IRD
  • Exchange
  • ICCM Nasdaq
  • IRD NYSE
  • Market Cap
  • ICCM 55.8M
  • IRD 62.0M
  • IPO Year
  • ICCM N/A
  • IRD N/A
  • Fundamental
  • Price
  • ICCM $0.99
  • IRD $0.93
  • Analyst Decision
  • ICCM Strong Buy
  • IRD Strong Buy
  • Analyst Count
  • ICCM 1
  • IRD 3
  • Target Price
  • ICCM $2.50
  • IRD $6.33
  • AVG Volume (30 Days)
  • ICCM 278.9K
  • IRD 2.9M
  • Earning Date
  • ICCM 08-19-2025
  • IRD 08-15-2025
  • Dividend Yield
  • ICCM N/A
  • IRD N/A
  • EPS Growth
  • ICCM N/A
  • IRD N/A
  • EPS
  • ICCM N/A
  • IRD N/A
  • Revenue
  • ICCM $3,273,000.00
  • IRD $13,651,000.00
  • Revenue This Year
  • ICCM $83.41
  • IRD $51.41
  • Revenue Next Year
  • ICCM $185.02
  • IRD $68.84
  • P/E Ratio
  • ICCM N/A
  • IRD N/A
  • Revenue Growth
  • ICCM 0.34
  • IRD N/A
  • 52 Week Low
  • ICCM $0.48
  • IRD $0.65
  • 52 Week High
  • ICCM $1.66
  • IRD $2.18
  • Technical
  • Relative Strength Index (RSI)
  • ICCM 46.56
  • IRD N/A
  • Support Level
  • ICCM $0.81
  • IRD N/A
  • Resistance Level
  • ICCM $1.03
  • IRD N/A
  • Average True Range (ATR)
  • ICCM 0.06
  • IRD 0.00
  • MACD
  • ICCM 0.01
  • IRD 0.00
  • Stochastic Oscillator
  • ICCM 75.00
  • IRD 0.00

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: